Oil Prices Rise as Hormuz Reopening Remains Uncertain 
US Dollar Falls as Weak July Jobs Report Dents Fed Rate Hike Bets 
Gold Prices Surge 7% as Dollar Falls, Fed Rate Hike Bets Ease 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
US Yen Intervention Unlikely to Deliver Lasting Recovery, Yardeni Says 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Australian Shares Fall as Westpac Slides, Miners Gain Ahead of RBA Decision 
Canada, US Hold Constructive Trade Talks as Tariff Negotiations Continue 
S&P 500, Nasdaq Futures Rise as Iran Risks and CPI Loom 
BOJ Rate Hike Expectations Rise Ahead of September Meeting 
European Stocks Flat as Oil Prices Rise, US CPI in Focus 
Shein Scales Back Vietnam Operations as US Trade Rules Shift 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
Goldman Sachs Sees US Stock Buybacks Outpacing Equity Issuance as AI Funding Rises 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
Johnson & Johnson is set to pay $230 million to settle a legal case over claims it encouraged and bolstered the opioid addiction predicament in the state of New York. Then again, it was mentioned that despite settling, the company did not acknowledge liability or any wrongdoing in what it was accused of.
What the J&J settlement means
As per BBC News, Johnson & Johnson settlement effectively prevented it from going to trial that is set to start on Tuesday, June 29. The hearing will present a number of opioid manufacturers and distributors as the defendants of the case.
The company said that its agreements with New York State are proportionate with the previous resolution to pay $5 billion to settle the opioid claims. It was added that the arrangement also requires Johnson & Johnson to discontinue the sale of painkillers across the country.
"The opioid epidemic has wreaked havoc on countless communities across New York state and the rest of the nation, leaving millions still addicted to dangerous and deadly opioids," Letitia James, the New York attorney general, said. "Johnson & Johnson helped fuel this fire, but today they're committing to leaving the opioid business - not only in New York but across the entire country."
J&J to take its problematic painkillers off the market
It was mentioned that addiction to opioids, both legal and illegal drugs, has become a serious issue, and this problem is ongoing in countries like the United States. In fact, based on the record of the Centers for Disease Control and Prevention, the country reported almost half a million deaths due to overdoses between the years 1999 and 2019.
While Johnson & Johnson is set to be removed from the trial in New York, it is still facing similar cases in other states such as California. At any rate, the deal with New York also asked the company to stop selling opioids, and it was learned that J&J already did so for some time now.
CNBC reported that Johnson & Johnson confirmed it has ended its opioid business a while ago, even before the settlement with New York. Since 2015, the company stopped marketing opioids in the U.S. and totally withdrew from the business in 2020.
